The current stock price of VTAK is 2.85 USD. In the past month the price increased by 25.11%. In the past year, price decreased by -58.52%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.6 | 213.46B | ||
| ISRG | INTUITIVE SURGICAL INC | 64.27 | 196.16B | ||
| BSX | BOSTON SCIENTIFIC CORP | 31.4 | 137.32B | ||
| SYK | STRYKER CORP | 26.44 | 133.19B | ||
| IDXX | IDEXX LABORATORIES INC | 55.23 | 55.61B | ||
| BDX | BECTON DICKINSON AND CO | 13.68 | 56.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.6 | 48.61B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.2 | 38.05B | ||
| RMD | RESMED INC | 25.23 | 36.46B | ||
| DXCM | DEXCOM INC | 36.22 | 26.27B | ||
| PODD | INSULET CORP | 64.54 | 20.75B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.45 | 18.35B |
Catheter Precision, Inc. engages in the design, manufacture, and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 22 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The firm's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is developing technology for the treatment of acute decompensated heart failure.
CATHETER PRECISION INC
1670 Highway 160 West, Suite 205
Fort Mill SOUTH CAROLINA US
Employees: 22
Phone: 19736912000
Catheter Precision, Inc. engages in the design, manufacture, and sale of medical devices and technologies for cardiac electrophysiology. The company is headquartered in Fort Mill, South Carolina and currently employs 22 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures by collaborating with physicians and continuously advancing its products. The firm's two primary products are the View into Ventricular Onset System (VIVO System) and LockeT. The VIVO System is a non-invasive imaging system that offers three-dimensional (3D) cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its product, LockeT, is a suture retention device indicated for wound healing by distributing suture tension over a larger area in the patient in conjunction with a figure of eight suture closure. Its product portfolio also includes the Amigo Remote Catheter System. The company is developing technology for the treatment of acute decompensated heart failure.
The current stock price of VTAK is 2.85 USD. The price increased by 2.15% in the last trading session.
VTAK does not pay a dividend.
VTAK has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
The Revenue of CATHETER PRECISION INC (VTAK) is expected to grow by 533.33% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
CATHETER PRECISION INC (VTAK) has a market capitalization of 4.76M USD. This makes VTAK a Nano Cap stock.
You can find the ownership structure of CATHETER PRECISION INC (VTAK) on the Ownership tab.
ChartMill assigns a technical rating of 3 / 10 to VTAK. When comparing the yearly performance of all stocks, VTAK is a bad performer in the overall market: 86.5% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to VTAK. Both the profitability and financial health of VTAK have multiple concerns.
Over the last trailing twelve months VTAK reported a non-GAAP Earnings per Share(EPS) of -73.84. The EPS increased by 70% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -94.12% | ||
| ROE | -354.3% | ||
| Debt/Equity | 0 |
7 analysts have analysed VTAK and the average price target is 38.76 USD. This implies a price increase of 1260% is expected in the next year compared to the current price of 2.85.
For the next year, analysts expect an EPS growth of 96.27% and a revenue growth 533.33% for VTAK